Qualification Type: | PhD |
---|---|
Location: | Milton Keynes |
Funding for: | UK Students |
Funding amount: | £19,237 per year (2024/25 rate, indexed annually) |
Hours: | Full Time |
Placed On: | 18th December 2024 |
---|---|
Closes: | 10th February 2025 |
Supervisory team: Dr Calum McMullen, Dr Katja Rietdorf and Dr Daniel Johnson (The Open University)
Location: The School of Life, Health and Chemical Sciences (LHCS), The Open University, Milton Keynes.
This project is part of a collaboration with an industry partner, Excellio Ltd. (Edinburgh, UK), and you will have the opportunity to complete a short placement (1 month) with Excellio to gain practical skills and industry experience.
Duration & Funding: Three years and 3 months from 1st October 2025
Stipend: £19,237 per year (2024/25 rate, indexed annually)
Project summary:
Anti-cancer drugs are known to inadvertently disrupt cellular dynamics in the heart, leading to structural and functional changes that ultimately can cause the heart to fail. Recent publications have suggested that extracellular vesicles (EVs) may play a role in this toxic mechanism (Yarana et al, 2022). Preliminary data collected by this research group demonstrated that EVs isolated from endothelial cells treated with the anti-cancer drug sunitinib malate led to a decrease in cell viability when introduced to healthy, untreated endothelial cells.
In this project we plan to progress this work to better understand the role EVs play in this process. We aim to (i) characterise the content of EVs isolated from cardiac cells treated with an anti-cancer drug; (ii) investigate the effect these EVs have on other cardiac cell types and elucidate the mechanism; and (iii) determine whether this cardiotoxic mechanism can be reduced/reversed by modulating EV uptake and/or content. The results of this project may lead to the identification of a novel component of the cardiotoxic mechanism that could serve as a target for pharmacological intervention to reduce/reverse this toxicity.
Further information:
This three-year research studentship is funded by the Faculty of Science, Technology, Engineering and Mathematics (STEM) at The Open University and provides a stipend of £19,237 per year (2024/25 rate, indexed annually) and all academic fees are covered.
The project is supervised by Dr Calum McMullen (Principal Investigator), Dr Katja Rietdorf and Dr Daniel Johnson (Co-Investigators). The student would be required to live in the UK and within commuting distance of The Open University in Milton Keynes.
Applicants will be expected to have a good undergraduate degree (upper second class or higher) in Pharmacology, Biomedical Science, Biology, Biochemistry, or a related area.
Though previous experience in the following is not essential (all of the techniques required for this project can be learned), this project would be well-suited to candidates who:
Most importantly, applicants should have a passion for science and a willingness to learn.
Informal enquiries relating to the project should be directed to Dr Calum McMullen (email: calum.mcmullen@open.ac.uk).
How to Apply:
Please send an email with your CV, a completed application form and a personal statement (max. 2 pages outlining your suitability for the studentship, what you hope to achieve from the PhD and your research experience to date) to STEM-LHCS-PHD@open.ac.uk via the above ‘Apply’ button.
You can find more information about this project via the following link: Investigating the Mechanistic Role of Extracellular Vesicles in Anti-cancer Drug Induced Cardiotoxicity
Prove your English language abilities with a secure English language test (SELT)
See further information here. We recommend an IELTS SELT Consortium test.
Closing date: Monday, 10th February 2025
Interview date: Week commencing 24th February 2025 via Microsoft Teams
LHCS holds Athena Swan Bronze Status. We promote diversity in employment and welcome applications from all sections of the community.
Type / Role:
Subject Area(s):
Location(s):